13 known cases. View patent page →
Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.
Jazz sued Teva over Teva's ANDA for generic Xywav; the complaint lists the '426 patent among the patents-in-suit. Teva filed invalidity contentions and counterclaims; the case was consolidated with the Lupin actions on Dec. 15, 2023, and remains ongoing with no final judgment on '426 found.
Jazz sued Alkem in a Xyrem-related ANDA action; the complaint asserted the '426 patent plus other patents. The case was voluntarily dismissed, with a Rule 41(a)(1)(A)(i) order signed Oct. 5, 2023, and the case terminated.
Jazz sued Tris Pharma over Tris's January 2026 Section 505(b)(2) NDA for generic Xyrem/Xywav; this docket lists the '426 patent among asserted patents and also lists '400, '181, '494, '446, '306, and '302. The matter appears active.
MDL antitrust litigation in N.D. Cal. in which US 6,780,889 is listed among the patents at issue, along with US 10,213,400, US 10,864,181, and US 7,262,219, among others. The claims are antitrust, not patent infringement.
Jazz Pharmaceuticals Ireland Ltd. sued Granules India Limited; 14 patents were asserted including the '400 patent. The case was terminated by consent judgment dismissing with prejudice on 2026-03-26.
Related/consolidated docket to the Lupin Xywav case; no further details provided.
DrugPatentWatch lists the '400 patent in this Avadel matter; the exact case number and whether the '400 patent was actually asserted could not be independently confirmed. It is listed as terminated Oct 27, 2025.
DrugPatentWatch lists the '400 patent in this Avadel matter; the exact case number and whether the '400 patent was actually asserted could not be independently confirmed. It is listed as pending/ongoing.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; settled and voluntarily dismissed with prejudice July 16, 2025.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; terminated at N.D. Ill. July 15, 2020.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; terminated at N.D. Ill. July 14, 2020.
Consolidated Xyrem antitrust MDL in N.D. Cal.; the '400 patent appears in pleadings as part of the alleged Xyrem patent/settlement thicket. A $145 million class settlement was granted preliminary approval May 16, 2025, with remaining claims set for trial March 2, 2026.